[Correspondence] AI-supported mammography screening: measuring benefit

This text is a response to the MASAI clinical trial, which focused on breast cancer screening. The mentioned MASAI trial evaluated mammography screening supported by artificial intelligence. This innovative approach using artificial intelligence was compared with standard double reading of mammograms. The authors point out that interval cancer rates and observed sensitivity depend on multiple factors. These indicators are shaped not only by the accuracy of the test itself but also by tumor biology. The duration of the preclinical-detectable phase also plays an important role in measuring the benefit.